Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 EP113 | DOI: 10.1530/endoabs.70.EP113

Sanatorio Méndez, Endocrinology, Buenos Aires, Argentina

Zoledronic acid (ZA) treatment increases bone mineral density (BMD), decreases bone turnover markers and reduces the risk of fractures in patients with osteoporosis (1).

Objective: Observe and quantify the changes in BMD and bone turnover markers in postmenopausal osteoporosis (PO) patients treated annually with zoledronic acid 5 mg intravenously.

Material and Methods: Medical records (MR) of PO patients whom received ZA from 2007 to 2017 were retrospective evaluated. Parametric test (paired T-test for quantitative variable) × 2 for qualitative variable were performed following variable distribution. Kaplan Meier- log rank test, lineal and cox regression were performed. SPSS and Stata14.0 software were used for statistical analysis.

Results: 130 women were included

Age (years)68.1 ± 9.4
BMI(Kg/m2)25.7 ± 5.1
Menopause age49 ± 5.6
Previous fracture45.4% (n = 59/130)
Vertebral fractures47.4% (n = 28/59)
Non–vertebral fractures61% (n = 36/59
Multiple fractures30.5% (n = 18/ 59)

A percentage of 50.8% had received prior treatment with oral bisphosphonates for a time period of 1.7 ± 2.4 years, 15 patients received others previous treatments.

The major prescription for ZA was: lack of response to oral bisphosphonates 36.2% (n = 47/130), very low bone mass density (T-sc < –3.5): 31.5% (n = 41/130), new fracture under treatment with oral bisphosphonates: 7.7% (n = 10/130), digestive intolerance to oral bisphosphonates 24.6% (n = 32/130) and previous history of fx: 45.4% (n = 59/130).

From total 84 patients received 2 infusions and 45 patients, 3 infusions with ZA respectively.

Adverse events were observed in 4.6% (n = 8) of patients.

One year after ZA, there was a significant increase at lumbar spine(LS) BMD in 3.7% (n = 0.009) and total hip (TH) 4.5% (P = 0.004), however in the following years the increase was not significant in both regions. There were no significant changes in femoral neck (FN).

There was a significant decrease 49% (P < 0.001) in C–telopeptide of type I collagen (CTX) values, but only after the first year of infusion.

Conclusions: In our cohort the annual treatment with intravenous ZA 5 mg produced a significant increase in BMD for LS and TH and a significant decrease in CTX per year. Adverse effects were uncommon. We believe that this study despite its limitations, provides useful information regarding the effectiveness and safeness of ZA as a therapeutic option for PO treatment.

Volume 70

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.